TruScreen: A world without cervical cancer — how to eliminate to most preventable cancer
July 2022: TruScreen Group Limited (NZX/ASX:TRU) is an Australia and New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening devices that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health, and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, Saudi Arabia and, Zimbabwe, where no large-scale cervical cancer screening programs and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.
_________________________________
Learn more: www.truscreen.com
-
Category
No comments found